Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Recent Advances in Vaccine Delivery
share announcement

Recent Advances in Vaccine Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 7560

Special Issue Editors

Dr. Diganta B. Das

E-Mail Website
Guest Editor
Department of Chemical Engineering, School of Aeronautical, Automotive, Chemical and Materials Engineering (AACME), Loughborough University, Loughborough LE11 3TU, UK
Interests: water and soil security; wastewater treatment
Special Issues, Collections and Topics in MDPI journals
Dr. Md Jasim Uddin

E-Mail Website
Guest Editor
Department of Pharmaceutical Technology, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, Malaysia
Interests: 3D printing; medical device; microneedles
Dr. Mostafa Mabrouk

E-Mail Website
Guest Editor
Refractories, Ceramics and Building Materials Department, (Biomaterials Group), National Research Centre, 33El Bohouth St. (former EL Tahrir St.), Dokki, P.O. 12622 Giza, Egypt
Interests: drug delivery systems; biomaterials; tissue engineering; nanomaterials; hydrogels
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Dennis Douroumis

E-Mail Website
Guest Editor
Faculty of Engineering and Science, School of Science, University of Greenwich, Chatham Maritime, Chatham, Kent ME4 4TB, UK
Interests: 3D printing technologies for pharmaceutical dosage forms or novel medical devices (microneedles, bioresorbable scaffolds); continuous manufacturing processes for the development of medicinal products; nanomaterial synthesis and surface modification for cancer treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We would like to invite you to contribute to the Special Issue (SI) entitled Recent Advances in Vaccine Delivery.

This SI will focus on highlighting innovative recent developments pertaining to vaccine delivery, as discussed below.

Vaccines are delivered to stimulate the body's immune response against specific infectious agents or diseases. Vaccines are typically delivered via oral and parenteral routes of administration. However, it is well known that these routes possess several limitations, and, therefore, alternative routes for vaccine drug delivery, which overcome the limitations of the traditional routes, could be useful. In addition, the production methods and safety of the vaccine, as well as other societal, political and financial issues, determine the success of a vaccine development and delivery programme.

In view of the above, we welcome your research or review papers on one or more of the following topics, in addition to any other that is related to the theme of the SI:

  1. Vaccine production and formulation;
  2. Digitalisation of vaccine production systems;
  3. Design of materials and devices for vaccine delivery;
  4. Methods of targeting sites for vaccine delivery;
  5. Vaccine design; pharmacokinetics, bioavailability and patient safety (clinical and preclinical trials);
  6. Societal, financial, environmental and political issues in vaccine production, delivery and availability;
  7. Use of biomaterials as possible carriers for vaccine delivery; 
  8. Biosafety issues related to vaccine delivery;
  9. Delivery strategies for new vaccine formulations;
  10. Scale up and technology transfer of vaccine formulations for clinical studies;
  11. Regulatory authorisation and commercialisation of vaccines.   

We look forward to your active participation in this endeavour and to receiving your contributions.

Dr. Diganta B. Das
Dr. Md Jasim Uddin
Dr. Mostafa Mabrouk
Prof. Dr. Dennis Douroumis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine production and formulation
  • digitalisation of vaccine production systems
  • design of materials and devices for vaccine delivery
  • methods of targeting sites for vaccine delivery
  • vaccine design
  • pharmacokinetics, bioavailability and patient safety (clinical and preclinical trials)
  • societal, financial, environmental and political issues in vaccine production, delivery and availability
  • use of biomaterials as possible carriers for vaccine delivery
  • biosafety issues related to vaccine delivery
  • delivery strategies for new vaccine formulations
  • scale up and technology transfer of vaccine formulations for clinical studies
  • regulatory authorisation and commercialisation of vaccines

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 1442 KiB  
Article
Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after Respiratory Immunization
by Jacob E. Parriott, Jason P. Stewart, D. David Smith, Stephen M. Curran, Christopher D. Bauer, Todd A. Wyatt, Joy A. Phillips, Elizabeth Lyden, Geoffrey M. Thiele and Joseph A. Vetro
Pharmaceutics 2022, 14(9), 1843; https://doi.org/10.3390/pharmaceutics14091843 - 01 Sep 2022
Viewed by 1950
Abstract
Generating long-lived mucosal and systemic antibodies through respiratory immunization with protective antigens encapsulated in nanoscale biodegradable particles could potentially decrease or eliminate the incidence of many infectious diseases, but requires the incorporation of a suitable mucosal immunostimulant. We previously found that respiratory immunization [...] Read more.
Generating long-lived mucosal and systemic antibodies through respiratory immunization with protective antigens encapsulated in nanoscale biodegradable particles could potentially decrease or eliminate the incidence of many infectious diseases, but requires the incorporation of a suitable mucosal immunostimulant. We previously found that respiratory immunization with a model protein antigen (LPS-free OVA) encapsulated in PLGA 50:50 nanoparticles (~380 nm diameter) surface-modified with complement peptide-derived immunostimulant 02 (CPDI-02; formerly EP67) through 2 kDa PEG linkers increases mucosal and systemic OVA-specific memory T-cells with long-lived surface phenotypes in young, naïve female C57BL/6 mice. Here, we determined if respiratory immunization with LPS-free OVA encapsulated in similar PLGA 50:50 microparticles (~1 μm diameter) surface-modified with CPDI-02 (CPDI-02-MP) increases long-term OVA-specific mucosal and systemic antibodies. We found that, compared to MP surface-modified with inactive, scrambled scCPDI-02 (scCPDI-02-MP), intranasal administration of CPDI-02-MP in 50 μL sterile PBS greatly increased titers of short-term (14 days post-immunization) and long-term (90 days post-immunization) antibodies against encapsulated LPS-free OVA in nasal lavage fluids, bronchoalveolar lavage fluids, and sera of young, naïve female C57BL/6 mice with minimal lung inflammation. Thus, surface modification of ~1 μm biodegradable microparticles with CPDI-02 is likely to increase long-term mucosal and systemic antibodies against encapsulated protein antigen after respiratory and possibly other routes of mucosal immunization. Full article
(This article belongs to the Special Issue Recent Advances in Vaccine Delivery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

47 pages, 6754 KiB  
Review
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
by Jasmin Hassan, Charlotte Haigh, Tanvir Ahmed, Md Jasim Uddin and Diganta B. Das
Pharmaceutics 2022, 14(5), 1066; https://doi.org/10.3390/pharmaceutics14051066 - 16 May 2022
Cited by 11 | Viewed by 4497
Abstract
To prevent the coronavirus disease 2019 (COVID-19) pandemic and aid restoration to prepandemic normality, global mass vaccination is urgently needed. Inducing herd immunity through mass vaccination has proven to be a highly effective strategy for preventing the spread of many infectious diseases, which [...] Read more.
To prevent the coronavirus disease 2019 (COVID-19) pandemic and aid restoration to prepandemic normality, global mass vaccination is urgently needed. Inducing herd immunity through mass vaccination has proven to be a highly effective strategy for preventing the spread of many infectious diseases, which protects the most vulnerable population groups that are unable to develop immunity, such as people with immunodeficiencies or weakened immune systems due to underlying medical or debilitating conditions. In achieving global outreach, the maintenance of the vaccine potency, transportation, and needle waste generation become major issues. Moreover, needle phobia and vaccine hesitancy act as hurdles to successful mass vaccination. The use of dissolvable microneedles for COVID-19 vaccination could act as a major paradigm shift in attaining the desired goal to vaccinate billions in the shortest time possible. In addressing these points, we discuss the potential of the use of dissolvable microneedles for COVID-19 vaccination based on the current literature. Full article
(This article belongs to the Special Issue Recent Advances in Vaccine Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop